Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
09 Maio 2023 - 5:01PM
Business Wire
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical
company dedicated to the development of innovative therapeutics to
treat seizure disorders, today announced the grant of inducement
awards to five new employees. The Compensation Committee of the
Board of Directors of Marinus approved the grant of non-qualified
stock options to purchase an aggregate of 50,400 shares of its
common stock (the “Common Stock”) as inducements material to the
employees entering into employment with the Company in accordance
with Nasdaq Listing Rule 5635(c)(4).
These stock option grants have an exercise price of $9.16 per
share, which is equal to the closing price of the Common Stock on
May 8, 2023 (first business day following May 6, 2023 date of grant
for such stock options). All of the stock options will vest and
become exercisable as to 25% of the underlying shares on the
one-year anniversary of the applicable employee’s start date of
employment, and will vest and become exercisable as to the
remaining 75% of the underlying shares of Common Stock in 36 equal
monthly installments thereafter on each monthly anniversary,
subject to the applicable employee’s continued employment with
Marinus on such vesting dates. The stock options were granted as an
inducement material to each of the employees entering into
employment with Marinus in accordance with Nasdaq Listing Rule
5635(c)(4), and are subject to the terms and conditions of the
applicable award agreement covering such grant.
About Marinus Pharmaceuticals Marinus is a commercial
stage pharmaceutical company dedicated to the development of
innovative therapeutics for seizure disorders. The Company’s
commercial product, ZTALMY® (ganaxolone) oral suspension CV, has
been approved by the U.S. FDA for the treatment of seizures
associated with CDKL5 deficiency disorder in patients two years of
age and older. The potential of ganaxolone is also being studied in
other rare seizure disorders, including in Phase 3 trials in
tuberous sclerosis complex and refractory status epilepticus.
Ganaxolone is a neuroactive steroid GABAA receptor modulator that
acts on a well-characterized target in the brain known to have
anti-seizure effects. It is being developed in IV and oral
formulations to maximize therapeutic reach for adult and pediatric
patients in acute and chronic care settings. For more information
visit www.marinuspharma.com.
Forward-Looking Statements To the extent that statements
contained in this press release are not descriptions of historical
facts regarding Marinus, they are forward-looking statements
reflecting the current beliefs and expectations of management made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Words such as “may”, “will”,
“expect”, “anticipate”, “estimate”, “intend”, “believe”, and
similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) are
intended to identify forward-looking statements. Forward-looking
statements in this press release involve substantial risks and
uncertainties that could cause our clinical development programs,
future results, performance or achievements to differ significantly
from those expressed or implied by the forward-looking statements.
Marinus undertakes no obligation to update or revise any
forward-looking statements. For a further description of the risks
and uncertainties that could cause actual results to differ from
those expressed in these forward-looking statements, as well as
risks relating to the business of the Company in general, see
filings Marinus has made with the Securities and Exchange
Commission.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230509005832/en/
Company Contact Sasha Damouni Ellis Senior Vice
President, Corporate Affairs & Investor Relations Marinus
Pharmaceuticals, Inc. sdamouni@marinuspharma.com
Marinus Pharmaceuticals (NASDAQ:MRNS)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Marinus Pharmaceuticals (NASDAQ:MRNS)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024